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A number of trimethylsiloxyalkyl and trialkylsilylalkyl thiazole derivatives have been evaluated for their anti-inﬂammatory activ-
ity, lipoxygenase inhibiting properties, and cytotoxicity. The investigated compounds have been found to protect in vivo against
carrageenin-induced edema, especially 3-(4-trimethylsiloxypiperidin-1-yl)-N-(thiazol-2-yl)-propionamide (21) and 2-amino-3-
(γ-trimethylsilylpropyl)thiazolium iodide (22), which exhibited good anti-inﬂammatory activity: 57.2% CPE inhibition in dose of
0.2mmol/kg for compound 21 and 55.0% in dose of 0.01mmol/kg for compound 22. All the compounds tested inhibited soybean
lipoxygenase activity. 2-(4-Trimethylsilyloxypiperidin-1-yl)-N-[4-( p-methoxyphenyl)-thiazol-2-yl]-acetamide (19)w a st h em o s t
potent displaying inhibition against lipoxygenase (ID50 = 0.01mmol). It also possessed moderate cytotoxic eﬀect (LC50 = 13
μg/mL, 3 ×10
−8 mmol/mL) concerning MG-22A cell lines.
Copyright © 2007 Athina Geronikaki et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
The aim of this investigation was to study anti-inﬂammatory
as well as lipoxygenase inhibitory activities and cytotoxicity
of a series of organosilicon-containing thiazole derivatives.
It is well known that thiazolyl derivatives possess anti-
inﬂammatory activity [1–6]. Today requirements demand
novel medicinal remedies possessing diﬀerent degrees of se-
lectivity and speciﬁcity depending on their purpose. Process
of inﬂammation often becomes chronic, and the human or-
ganism needs drugs therapy support in periods of acute at-
tacks. Therefore, increase of the variety of speciﬁc and selec-
tive anti-inﬂammatory remedies is an important task, espe-
cially due to its positive inﬂuence on the chronic sick rate
decrease. Some anticancer drugs as blenoxane, bleomycine,
andtiazofurin,containingthiazolylmoietyintheirstructure,
are known as antineoplastics [7]. Besides, several thiazolyl
derivativeswerefoundtobepotentantitumouragents[7–9].
Since arachidic acid (AA) metabolism results in the genera-
tion of mutagens that damage DNA and induce mutations,
members of arachidic acid enzymes, especially the lipoxyge-
nase pathway, have been reported to play a signiﬁcant role in
carcinogenesis. Inhibitors of AA metabolism can reverse the
production of these metabolites resulting in recruitment of
apoptotic cells clearance [10].
Organosiliconcompoundsattractscientiﬁcattentiondue
to some diﬀerent reasons, especially due to a number of in-
teresting results in the ﬁeld of their biological action. Mod-
ern organosilicon chemistry coincided with the emergence
of biomaterials and bioengineering ﬁelds ﬁfty years ago. It
has been reported that some organosilicon compounds af-
fect the collagen biosynthesis in cartilagenous tissue [11].
New approaches based on the organosilicon modiﬁcation
of the biologically active compounds, especially of com-
pounds containing hydrophilic functional groups, oﬀer the
real possibility to improve their pharmacological proper-
ties because of easier penetration of modiﬁed compounds
through lipophilic barriers inside the body [12, 13]. In this
paper,wereportthebiologicalactivityoftrimethylsilylethers
of thiazole derivatives, but the wide possibility for variation
of substituents around the silicon atom can lead to more ﬁne
selection of perspective compound for the investigations in
vivo.
2. EXPERIMENTAL
2.1. Chemistry
1H NMR spectra were recorded with a Mercury 200 (Varian)
spectrometer using CDCl3 as solvent and hexamethyld-2 Bioinorganic Chemistry and Applications
isiloxane (HMDSO) as internal standard (for unsilylated
compounds). Mass spectra under electron impact con-
ditions were recorded on a Hewlett-Packard apparatus
(HP-6890, GC with HP5MS, 70eV). Analytical thin-layer
chromatography (TLC) was performed on Macherey-Nagel
silica plastic plates, with visualization under UV (254mm).
Column chromatography was performed using Merck silica
gel (0.040–0.063mm). Solvents and reagents were purchased
from the following commercial sources: Fluka, Aldrich,
Acros. Melting points were determined on a Boetius melting
point apparatus and were uncorrected. Elemental analyses
were performed on Carlo Erba 1108 elemental analyzer.
Elemental analyses (C, H, N, S) for all compounds synthe-
sized were within ±0.4% of theoretical values. The following
compounds were synthesized according to literature pro-
cedures: 2-chloro-N-(thiazol-2-yl)-acetamide (1)[ 14, 15],
2-chloro-N-(4-phenylthiazol-2-yl)-acetamide (2)[ 14, 15],
2-chloro-N-[4-(p-methoxyphenyl)-thiazol-2-yl]-acetamide
(3)[ 14, 15], 2-chloro-N-(4-phenyl-5-tetradecylthiazol-2-
yl)-acetamide (4)[ 14, 15], 3-chloro-N-(thiazol-2-yl)-pro-
pionamide (5)[ 14, 15], 2-(4-hydroxypiperidin-1-yl)-N-
(thiazol-2-yl)-acetnamide (6)[ 6], 2-(4-hydroxypiperidin-1-
yl)-N-(4-phenylthiazol-2-yl)-acetamide (7)[ 6], 2-(4-hy-
droxypiperidin-1-yl)-N-[4-(p-methoxyphenyl)-thiazol-2-
yl]-acetamide (8)[ 6], 2-(4-hydroxypiperidin-1-yl)-N-(4-
phenyl-5-tetradecylthiazol-2-yl)-acetamide (9)[ 6], 3-(4-hy
droxypiperidin-1-yl)-N-(thiazol-2-yl)-propionamide (10)
[6], 4-methyl-5-(β-hydroxyethyl)-thiazole (11)[ 16], 4-
methyl-5-(β-trimethylsiloxyethyl)-thiazole (12)[ 17], 2-
amino-4-hydroxymethyl-thiazole (13)[ 18], 2-amino-4-
trimethylsiloxymethyl-thiazole (14)[ 17], 2-phenyl-4-hy-
droxymethyl-thiazole (15)[ 19], 2-phenyl-4-trimethylsilox-
ymethyl-thiazole (16)[ 17], 2-(4-trimethylsiloxypiperidin-
1-yl)-N-(4-phenylthiazol-2-yl)-acetamide (18)[ 17], 2-(4-
trimethylsiloxypiperidin-1-yl)-N-(4-phenyl-5-tetradecylthi-
azol-2-yl)-acetamide (20)[ 17], 3-(4-trimethylsiloxypiperi-
din-1-yl)-N-(thiazol-2-yl)-propionamide (21)[ 17], and
2-amino-3-(γ-trimethylsilylpropyl)thiazolium iodide (22)
[17].
2.1.1. 2-(4-trimethylsiloxypiperidin-1-yl)-N-(thiazol-2-yl)-
acetamide(17)
A mixture of 0.25mmol (60mg) of compound 6 and 2.5mL
of hexamethyldisilazane in 5mL of ether was heated for 25
hours until the precipitate was dissolved. The progress of the
reactionwasmonitoredbyTLC.Whenthereactionwascom-
plete, thesolventandexcessofhexamethyldisilazane werere-
moved in vacuum on a rotary evaporator. The residue was
puriﬁed by column chromatography on silica-gel (eluent –
petr. ether : EtOAc = 1 : 2) to give 71mg (91%) of the com-
pound 17 as oil. After some time, the crystalls were formed,
m.p. 103–105◦C.
1H NMR (200MHz, CDCl3,2 5 ◦C, HMDSO), δ, ppm:
0.12 (s, 9H, SiMe3), 1.71, 2.42 and 2.82 (m+m+m,
4H+2H+2H, CH2(cycl.)), 3.22 (s, 2H, COCH2N), 3.74
(s, 1H, CH(cycl.)O ) ,6 . 9 8( d ,1 H ,5 - H ) ,7 . 4 3( d ,1 H ,
4-H). GC-MS: M+ = 313 (13%); M+-15 (CH3) = 298
(2%); M+-127 (2-thiazolyl-NHCO) = 186 (100%); M+-141
(2-thiazolyl-NHCOCH2) = 172 (10%); M+-186 (CH2-N-
(piperidyl)OSiMe3) = 127 (8%). Element. anal. found, %:
C: 49.50; H: 7.45; N: 13.31; S: 9.03. C13H23N3O2SSi (MW =
313.497). Calculated, %: C: 49.81; H: 7.39; N: 13.40; S: 8.96.
2.1.2. 2-(4-trimethylsilyloxypiperidin-1-yl)-N-[4-(p-
methoxyphenyl)-thiazol-2-yl]-acetamide(19)
A mixture of 120mg (0.34mmol) of compound 8 and 3mL
of hexamethyldisilazane in 5mL of ether was heated with
stirring for 100 hours until the precipitate was dissolved and
the new one was formed. The progress of the reaction was
monitored by TLC. When the reaction was complete, the
solvent and excess of hexamethyldisilazane were removed in
vacuum in a rotary evaporator. The solid was washed with
hexane to give 100mg (84%) of the compound 19, m.p. 125–
127◦C.
1H NMR (200MHz, CDCl3,2 5 ◦C, HMDSO), δ, ppm.:
0.12 (s, 9H, SiMe3); 2.79, 2.47 and 1.79 (m+m+m,
2H+2H+4H, CH2(cycl.)); 3.22 (s, 2H, COCH2N), 3.82 (s, 4H,
OCH3 +C H (cycl.)O); 7.01 (s, 1H, 5-H), 6.93 and 7.74 (d+d,
2H+2H, CH(arom)).
Element. anal. found, %: C: 57.14; H: 6.89; N: 10.06; S:
7.62. C20H29N3O3SSi (MW = 419,622). Calculated, %: C:
57.25; H: 6.97; N: 10.01; S: 7.64.
2.2. Biologicalassays
2.2.1. Carrageenin-inducedmicepawedema
inhibition[20]
AKR or A mice (20–30g, groups of ten) of both sexes were
used. Females pregnant were excluded. A single dose of
0.2mmol/kg body weight of compounds 12, 16, 20, 21 and
0.01mmol/kg of compound 22 or 0.013mmol/kg of com-
pound 14 suspended in water with few drops of Tween 80
was administered intraperitoneally simultaneously to the in-
tradermally injection of 0.05mL carrageenin in the right
hind paw. Indomethacin was used as a standard diluted
agent. Inhibition caused by indomethacin was 57.4% in dose
0.1mmol/kgbw.
2.2.2. Soybeanlipoxygenaseinhibition[21]
The tested compounds dissolved in DMSO or ethanol
(concentrations ranged from 0.1 to 1mM) were incubated
at room temperature with sodium linoleate (0.1mmol)
and 0.2mL of enzyme solution (250U/mL in saline). The
conversion of sodium linoleate to 13-hydroperoxylinoleic
acid at 234nm was recorded and compared with nordihy-
droguaretic acid (0.1mmol - 84%), an appropriate standard
inhibitor.
2.2.3. Cytotoxicity
Monolayer tumour cell lines MG-22A (mouse hepatoma),
HT-1080 (human ﬁbrosarcoma), and normal mouse ﬁbrob-
lasts (NIH 3T3) were cultivated for 72hours in DMEM
standard medium (Sigma) without an indicator and antibi-
otics. After the ampoule had thawed, cells from one to fourAthina Geronikaki et al. 3
passageswereusedinthreeconcentrationsoftestcompound:
1, 10 and 100μgm L −1. The control cells and cells with
tested compounds in the range of 2–5∗104 cell mL−1 con-
centration (depending on line nature) were placed on sep-
arate 96 wells plates. Solutions containing test compounds
were diluted and added in wells to give the ﬁnal concentra-
tions. Control cells were treated in the same manner only
in the absence of test compounds. Plates were cultivated
for 72hours. The number of survived cells was determined
using crystal violet (CV), 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolinium bromide (MTT), or neutral red (NR)
coloration which was assayed by multiscan spectrophotome-
ter. The quantity of alive cells on control plate was taken in
calculations for 100% [22, 23]. The LC50 was calculated us-
ing Graph Pad Prism 3.0 program, r<. 05. Concentration of
NO was determined according to [23].
3. RESULTS AND DISCUSSION
Thiazole derivatives of general formula presented in Figure 1
have been studied.
N-(2-thiazolyl)amides, containing 4-hydroxypiperidine
residue, were synthesized by consecutive condensation reac-
tions:2-aminothiazolereactedwithappropriateacylchloride
(chloroacetic or chloropropionic acid chlorides) to give the
respective chloroalkylamides (1–5)[ 14, 15], then the reac-
tion of the prepared chloroalkylamides with N-containing
heterocycle, 4-hydroxypiperidine, gave the corresponding
thiazolyl amides (6–10)[ 6]. The organosilicon derivatives
have been prepared in two ways: (a) by introducing of O-
silyl group into hydroxyl-containing thiazole compounds, to
obtain the compounds 12, 14, 16, 17–21, and (b) by intro-
ducing C-silyl group using quarternization reaction of nitro-
gen to obtain the compound 22 [17]. The general synthetic
methods employed are shown in Figure 2.
Structures of the compounds prepared were conﬁrmed
by 1H-NMR, GC-MS spectroscopy, and by elemental anal-
ysis. Theoretical calculations of lipophilicity as clog P
for compounds synthesized, using the method of additiv-
ity, were performed [24]( Table 1). We investigated anti-
inﬂammatory and lipoxygenase inhibitory activities and cy-
totoxicity of organosilicon-containing thiazole derivatives.
Organosilicon-containing compounds 12, 14, 16, 20–22
were examined in vivo for their anti-inﬂammatory activity
using the carrageenin mice paw edema (CPE) as a model of
inﬂammation. The in vivo anti-inﬂammatory eﬀects of the
tested thiazole derivatives were assessed by using the func-
tional model of carrageenin-induced rat paw edema and are
presented in Table 1 as percentage of weight increase at the
right hind paw in comparison to the uninjected left hind
paw.
Carrageenin-induced edema is a nonspeciﬁc inﬂamma-
tion resulting from a complex of diverse mediators [2]. Since
edemas of this type are highly sensitive to nonsteroidal anti-
inﬂammatory drugs (NSAIDs), carrageenin has been ac-
cepted as a useful agent for studying new anti-inﬂammatory
drugs [25]. This model reliably predicts anti-inﬂammatory
eﬃcacy of the NSAIDs, and during the second phase it
Table 1: Theoretically calculated lipophilicity clog P,I C 50 or % in-
hibitionvaluesforlipoxygenase(LOX)and%carrageeninmicepaw
edema inhibition (CPE%) of trimethylsiloxylalkyl thiazole deriva-
tives 12, 14, 16–22. ND denotes nondetermined.
Compound CPE%(a) clog P(b) IC50 LOX
12 24∗∗ 3.880 9.1%
(0.1mmol)
14 35.5∗
2.260 0.1mmol
(0.013mmol/kg)
16 47.6∗ 5.540 0.47mmol
17 ND 1.700 0.35mmol
18 ND 5.666 66.7%
(0.1mmol)
19 ND 3.939 0.01mmol
20 38.3∗ 13.470 40.8%
(0.1mmol)
21 57.2∗ 3.765 ND
22 55.0∗
4.399(c) 0.46mmol
(0.01mmol/kg)
Indomethacin 57.2 — —
(a) dose 0.2mmol/kgbw.
(b) theoretically calculated values using the clog P program from Biobyte.
(c) calculated for the base.
∗ P<. 05.
∗∗ P<. 01.
detects compounds which are anti-inﬂammatory agents as a
result of inhibition of prostaglandin ampliﬁcation.
The studied compounds 12, 14, 16, 20–22 were found
to protect in vivo against edema formation. Analyzing the
data obtained, it is revealed that 21 and 22 were more po-
tent among all the compounds tested. Compound 21 ex-
hibited similar to indomethacin inhibition—57.2%, but in
double dose (0.2mmol/kgbw). Organosilicon salt 22 was
found to be the most potent inhibitor, possessing about
the same as indomethacin inhibition (55.0%), but in lower
dose(0.01mmol/kgbw).4,5-disubstituedthiazolewithout2-
substituent (12) was found to be the least active compound.
The compounds 12, 14, 16–20,a n d22 were evaluated
for inhibition of soybean lipoxygenase (LOX) by the UV-
absorbance-based enzyme assay [26]. While one may not ex-
trapolate the quantitative results of this assay to the inhi-
bition of mammalian 5-LOX, it has been shown that inhi-
bition of plant lipoxygenase activity by NSAIDs is qualita-
tively similar to their inhibition of the rat mast cell lipoxyge-
nase and may be used as a simple qualitative screen for such
activity. The results are presented in Table 1. All the tested
compounds were found to inhibit soybean lipoxygenase. The
IC50 values for compounds 14, 16, 17, 19,a n d22 were deter-
mined. They ranged within 0.01–0.47mmol. For other com-
pounds (12, 18,a n d20) persentage of inhibition at concen-
tration 0.1mmol was determined.
It has been revealed that among trimethylsilox-
yalkyl/trimethylsilylalkyl thiazole derivatives (12, 14, 16,
and 22), compound 14, containing 2-amino group, was the
most active as lipoxygenase inhibitor (IC50 = 0.1mmol),4 Bioinorganic Chemistry and Applications
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Figure 1: Structure of thiazole derivatives 1–21.
but 12 w i t h o u ts u b s t i t u e n ta tC 2-position of thiazole cycle
was found to be the least active compound in this respect.
It inhibits lipoxygenaze action only by 9.1% in dose of
0.1mmol.
It was found that among organosilicon-containing 2-
thiazolyl-amides 17–20, the presence of substituent in C4-
position of thiazole ring is essential for lipoxygenase inhibi-
tion display. Compounds 19 and 18 were the most potentAthina Geronikaki et al. 5
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Figure 2: Synthesis of organosilicon derivatives of thiazole.
lipoxygenase inhibitors (IC50 = 0.01mmol, and 66.7% inhi-
bition in dose of 0.1mmol, correspondingly). Compound
19 was the most active lipoxygenaze inhibitor also among
all compounds tested. It was also revealed that the nature
of C4-substituent inﬂuences the degree of inhibition: 4-
methoxyphenylderivative(19)wasabetterinhibitorincom-
parison with its 4-phenyl analog (18). Introduction of addi-
tional bulky substituent in C5-position of the molecule was
telling on the level of inhibition. Thus, compound 20 pos-
sessed lower inhibiting properties (by 26%) in comparison
with C5-unsubstituted compound 18.C o m p o u n d17 with-
out substituent at C4-position of thiazole ring was the least
potent inhibitor (IC50 = 0.35mmol). Concerning the corre-
lation of lipophilicity—CPE and lipoxygenase inhibition—it
was revealed that these parameters do not proceed in parallel
along the compounds investigated.
The experimental evaluation of cytotoxicity of com-
pounds 6, 8, 17,a n d19 is presented in Table 2.
Compound 8 and its trimethylsilyl ether 19 possess
low cytotoxic eﬀect on human ﬁbrosarcoma HT-1080 (LC50
> 100μg/mL) and moderate eﬀect on mouse hepatoma
MG-22A (LC50 = 17 and 21μg/mL, correspondingly, CV,
and LC50 = 16 and 13μg/mL, correspondingly, MTT col-
oration). Compound 6 and its trimethilsilyl ether 17 with-
out substituents at C4-a n dC 5-positions of thiazole do not
exhibit cytotoxic properties. Both compounds decrease MG-
22A cell growing by up to 40% (MTT coloration), but at
the same time, stimulated HT-1080 cell growing at all stud-
ied concentrations by up to 55% (CV). No signiﬁcant dif-
ference among compounds was determined comparing their
NO-generation ability in HT-1080 cell lines. Compound
19 possessed the highest NO-generation activity concerning
MG-22Atumourcells.Allstudiedcompoundswerenontoxic
compounds concerning normal cells NIH 3T3.
Analyzing the results obtained for 2-thiazolyl amides
6, 8, 17, 19 and previously published data on cytotoxic-
ity of silylated compounds 18, 20, 21 and their nonsily-
lated precursors 7, 9, 10 [17], it was revealed that all 4-
trimethylsiloxypiperidine derivatives of 2-thiazolyl amides
17–21 possessed low or moderate cytotoxic eﬀect concern-
ing either human ﬁbrosarcoma (LC50 = 44–77μg/mL) or
mouse hepatoma (LC50 = 13–59μg/mL), excluding com-
pound 17, which was inactive in both tests. The strongest
cytotoxic eﬀect on mouse hepatoma was observed for
18 (LC50 = 5.3μg/mL, CV test). It can be noted that all
2-thiazolyl amides, which have bulky substituent in C4-
position of thiazole ring (compounds 7–9 and 18–20), ex-
hibited moderate eﬀect on MG-22A cell line (LC50 = 5.3–
37μg/mL, CV). Among unsilylated compounds 7–9, the
most lipophilic 9 (clog P = 9.134) with additional tetradecyl
substituent in C5-position possesses the highest cytotoxicity
on MG-22A cell line (LC50 = 8μg/mL, CV).
The distance elongation between thiazolyl and piperidyl
heterocycles, either in unsilylated compounds 6, 10 or
silylated ones 17, 21, leads to cytotoxic eﬀect appear-
ance for propionamides 10 and 21, concerning human ﬁ-
brosarcoma (LC50 = 48μg/mL and 44μg/mL, correspond-
ingly) or its essential increase, concerning mouse hepatoma
(LC50 = 35μg/mL for 10 and 44μg/mL for 21,C V ) ,i nc o m -
parison with the corresponding acetamides 6 and 17.6 Bioinorganic Chemistry and Applications
Table 2: In vitro cytotoxicity against various cell lines and ability of intracellular NO generation caused by thiazolyl-(6), 4-(p-
methoxyphenyl)thiazolyl-(4-hydroxypiperidyl)acetamide (8), and their silyl ethers 17 and 19.
HT-1080 MG-22A NIH 3T3
Compound LC50
(a) LC 50
(a) NO(b) LC50
(a) LC50
(a) NO(b) LC50
(a) LD50,
CV MTT CV CV MTT CV NR mg/kg
6 —(c) —(c) 4 —(c) > 100 6 —(c) > 2000
8 > 100 100 8 17 16 75 185 1110
17 —(c) —(c) 11 —(c) —(c) 23 937 2132
19 100 100 27 21 13 122 72 839
(a) Concentration (μg/mL) providing 50% cell killing eﬀect (CV, MTT, and NR coloration).
(b) No generation (CV coloration), determined according to [23].
(c) No cytotoxic eﬀect.
The introduction of trimethylsilyl group into com-
pound 7 caused the cytotoxic eﬀect increase concerning
mouse hepatoma, which was revealed as the highest for 18
(LC50 = 5.3μg/mL), among all the compounds studied.
4. CONCLUSIONS
The organosilicon thiazoles studied were found to a cer-
tain extent to protect in vivo against edema formation and
to inhibit soybean lipoxygenase. Organosilicon salt 22 was
the most potent as anti-inﬂammatory agent among all com-
pounds tested and indomethacin.
The nature of substituent in C4-position of thiazole ring
is essentially telling on the degree of lipoxygenase inhibi-
tion and cytotoxic activity. The most active as lipoxyge-
nase inhibitor was 2-(4-trimethylsilyloxypiperidin-1-yl)-N-
[4-(p-methoxyphenyl)-thiazol-2-yl]-acetamide (19), which
contains bulky p-MeO-C6H4-group at C4-position.
The distance elongation between thiazolyl and piperidyl
heterocycles either in parent compounds (6, 10) or their silyl
ethers (17, 21) leads to cytotoxic eﬀect noticeable increase
for propionamides 10 and 21 in comparison with the corre-
sponding acetamides 6 and 17. Trimethylsilyl ether 18 was
the most active against mouse hepatoma among all the com-
pounds studied and in comparison with its unsilylated pre-
cursor 7.
It can be noted that the data obtained do not allow to
conclude deﬁnitely the existence of relationship among anti-
inﬂammatory activity, lipoxygenase inhibition, and cytotox-
icity. But in some cases, cytotoxic properties were accompa-
nied by anti-inﬂammatory activity (organosilicon salt 22)o r
lipoxygenase inhibition activity display (thiazolyl acetamides
18 and 19). At the same time, compound 4-methyl-5-(β-
trimethylsiloxyethyl)-thiazole (12) was the least active con-
cerning all the biological properties studied.
The wide possibility for variation of substituents around
the silicon atom can promote ﬁner selection of perspective
compound for further investigations.
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